Clinical Development and Manufacture of Chimeric Antigen Receptor T cells and the Role of Leukapheresis

No abstract is available for this paper.

• Publication year

  2017

• Venue

  European Oncology and Haematology

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.17925/EOH.2017.13.01.28
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Myeloid cells in peripheral blood mononuclear cell concentrates inhibit the expansion of chimeric antigen receptor T cells.

  2016cited by this paper
• Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition.

  2016cited by this paper
• Chimeric Antigen Receptors Modified T-Cells for Cancer Therapy

  2016cited by this paper
• Current status and regulatory perspective of chimeric antigen receptor-modified T cell therapeutics

  2016cited by this paper
• Clinical manufacturing of CAR T cells: foundation of a promising therapy

  2016cited by this paper
• Driving CAR T-cells forward

  2016cited by this paper
• Distinct Signaling of Coreceptors Regulates Specific Metabolism Pathways and Impacts Memory Development in CAR T Cells.

  2016cited by this paper
• How Chimeric Antigen Receptor Design Affects Adoptive T Cell Therapy

  2016cited by this paper
• Clonally expanded CD4+ T cells can produce infectious HIV-1 in vivo

  2016cited by this paper
• Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor.

  2015cited by this paper
• T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial.

  2015cited by this paper
• Immunotherapy with Chimeric Antigen Receptor Targeting Intracellular WT1 Gene Product Complexed with HLA-a*24:02 Molecule

  2015cited by this paper
• Donor-derived CD19-targeted T cells in allogeneic transplants

  2015cited by this paper
• Tumor-Infiltrating Lymphocytes Genetically Engineered with an Inducible Gene Encoding Interleukin-12 for the Immunotherapy of Metastatic Melanoma

  2015cited by this paper
• Towards an HIV cure based on targeted killing of infected cells: different approaches against acute versus chronic infection

  2015cited by this paper
• Engineering T Cells to Functionally Cure HIV-1 Infection.

  2015cited by this paper
• Redirection of genetically engineered CAR-T cells using bifunctional small molecules.

  2015cited by this paper
• Remote control of therapeutic T cells through a small molecule–gated chimeric receptor

  2015cited by this paper
• 3D hotspots of recurrent retroviral insertions reveal long-range interactions with cancer genes

  2015cited by this paper
• Immunosuppressive FVIII-Specific Human Cartregs in Hemophilia a

  2015cited by this paper
• Sleeping Beauty Transposition of Chimeric Antigen Receptors Targeting Receptor Tyrosine Kinase-Like Orphan Receptor-1 (ROR1) into Diverse Memory T-Cell Populations

  2015cited by this paper
• Performance-enhancing drugs: design and production of redirected chimeric antigen receptor (CAR) T cells

  2015cited by this paper
• Genetically modified T cells in cancer therapy: opportunities and challenges

  2015cited by this paper
• Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia

  2015cited by this paper
• Design and implementation of adoptive therapy with chimeric antigen receptor‐modified T cells

  2014cited by this paper
• Managing Cytokine Release Syndrome Associated With Novel T Cell-Engaging Therapies

  2014cited by this paper
• Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia

  2014cited by this paper
• Unstimulated leukapheresis in patients and donors: comparison of two apheresis systems

  2014cited by this paper
• Of CARs and TRUCKs: chimeric antigen receptor (CAR) T cells engineered with an inducible cytokine to modulate the tumor stroma

  2014cited by this paper
• Possible reasons for variable leukapheresis collection outcomes with automated apheresis systems

  2014cited by this paper
• First comparative evaluation of a new leukapheresis technology in non‐cytokine‐stimulated donors

  2014cited by this paper
• Counter-flow elutriation of clinical peripheral blood mononuclear cell concentrates for the production of dendritic and T cell therapies

  2014cited by this paper
• Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma.

  2013cited by this paper
• Targeting the Intracellular WT1 Oncogene Product with a Therapeutic Human Antibody

  2013cited by this paper
• Focused ultrasound delivers targeted immune cells to metastatic brain tumors.

  2013cited by this paper
• Pattern of CD4 T-lymphocyte Values in Cancer Patients on Cytotoxic Therapy

  2013cited by this paper
• Identification of a Titin-Derived HLA-A1–Presented Peptide as a Cross-Reactive Target for Engineered MAGE A3–Directed T Cells

  2013cited by this paper
• The basic principles of chimeric antigen receptor design.

  2013cited by this paper
• T Cells Expressing Chimeric Antigen Receptors Can Cause Anaphylaxis in Humans

  2013influential reference
• Anti-PD-1 Antibody Therapy Potently Enhances the Eradication of Established Tumors By Gene-Modified T Cells

  2013cited by this paper
• Simplified process for the production of anti-CD19-CAR-engineered T cells.

  2013cited by this paper
• Mesothelin-Specific Chimeric Antigen Receptor mRNA-Engineered T Cells Induce Antitumor Activity in Solid Malignancies

  2013cited by this paper
• Gene-engineered T cells for cancer therapy

  2013cited by this paper
• Design of a Phase I Clinical Trial to Evaluate Intratumoral Delivery of ErbB-Targeted Chimeric Antigen Receptor T-Cells in Locally Advanced or Recurrent Head and Neck Cancer

  2013cited by this paper
• CAR/FoxP3-engineered T regulatory cells target the CNS and suppress EAE upon intranasal delivery

  2012cited by this paper
• Decade-Long Safety and Function of Retroviral-Modified Chimeric Antigen Receptor T Cells

  2012cited by this paper
• Anticoagulation techniques in apheresis: From heparin to citrate and beyond

  2012cited by this paper
• The blockade of immune checkpoints in cancer immunotherapy

  2012cited by this paper
• Whole transcriptome characterization of aberrant splicing events induced by lentiviral vector integrations.

  2012cited by this paper
• Expression of a Functional CCR2 Receptor Enhances Tumor Localization and Tumor Eradication by Retargeted Human T cells Expressing a Mesothelin-Specific Chimeric Antibody Receptor

  2011cited by this paper
• Immune responses to transgene and retroviral vector in patients treated with ex vivo-engineered T cells.

  2011cited by this paper
• Immunotherapy targeting HER2 with genetically modified T cells eliminates tumor-initiating cells in osteosarcoma

  2011cited by this paper
• State-of-the-art gene-based therapies: the road ahead

  2011cited by this paper
• Significant mobilization of both conventional and regulatory T cells with AMD3100.

  2011cited by this paper
• Eradication of melanomas by targeted elimination of a minor subset of tumor cells

  2011cited by this paper
• The Inside Out of Lentiviral Vectors

  2011cited by this paper
• Inducible apoptosis as a safety switch for adoptive cell therapy.

  2011cited by this paper
• Large volume leukapheresis: Efficacy and safety of processing patient's total blood volume six times.

  2011cited by this paper
• Lentiviral vector common integration sites in preclinical models and a clinical trial reflect a benign integration bias and not oncogenic selection.

  2011cited by this paper
• Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2.

  2010cited by this paper
• Selective Expansion of Chimeric Antigen Receptor-targeted T-cells with Potent Effector Function using Interleukin-4*

  2010cited by this paper
• Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor.

  2010cited by this paper
• Large-scale Ficoll gradient separations using a commercially available, effectively closed, system.

  2010cited by this paper
• Enhanced Tumor Trafficking of GD2 Chimeric Antigen Receptor T Cells by Expression of the Chemokine Receptor CCR2b

  2010cited by this paper
• Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19.

  2010cited by this paper
• Noninvasive in vivo imaging of CD4 cells in simian-human immunodeficiency virus (SHIV)-infected nonhuman primates.

  2009cited by this paper
• Plerixafor (AMD3100) and granulocyte colony-stimulating factor (G-CSF) mobilize different CD34+ cell populations based on global gene and microRNA expression signatures.

  2009cited by this paper
• Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo.

  2009cited by this paper
• Engineering lymphocyte subsets: tools, trials and tribulations

  2009cited by this paper
• Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients.

  2008cited by this paper
• Engineering artificial antigen-presenting cells to express a diverse array of co-stimulatory molecules.

  2007cited by this paper
• Principles of adoptive T cell cancer therapy.

  2007cited by this paper
• Accumulation of memory T cells from childhood to old age: central and effector memory cells in CD4(+) versus effector memory and terminally differentiated memory cells in CD8(+) compartment.

  2006cited by this paper
• Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience.

  2006cited by this paper
• Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration

  2006cited by this paper
• Genetic modification of hematopoietic cells using retroviral and lentiviral vectors: safety considerations for vector design and delivery into target cells.

  2005cited by this paper
• Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells

  2005cited by this paper
• GMP production and testing of Xcellerated T Cells for the treatment of patients with CLL.

  2004cited by this paper
• IL-7 surface-engineered lentiviral vectors promote survival and efficient gene transfer in resting primary T lymphocytes.

  2003cited by this paper
• Ex vivo expansion of polyclonal and antigen-specific cytotoxic T lymphocytes by artificial APCs expressing ligands for the T-cell receptor, CD28 and 4-1BB

  2002cited by this paper
• Large-Volume Leukapheresis Using Regional Citrate Anticoagulation to Collect Peripheral Blood Progenitor Cells

  1995cited by this paper
• Distribution of lymphocyte subsets and natural killer cells in the human body

  1992cited by this paper
• Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity.

  1989cited by this paper

• [Cell therapy in all its forms].

  2024cites this paper
• Cellules CAR-T et tumeurs solides : où en sommes-nous en France ?

  2024cites this paper
• Jump-starting chimeric antigen receptor-T cells to go the extra mile with nanotechnology.

  2024cites this paper
• CAR T Cell Therapy: A New Hope for Refractory Lupus?

  2023cites this paper
• Nanoparticle-Based Chimeric Antigen Receptor Therapy for Cancer Immunotherapy

  2023cites this paper
• Nanomedicine for advanced cancer immunotherapy.

  2022cites this paper
• Catching Them Early: Framework Parameters and Progress for Prenatal and Childhood Application of Advanced Therapies

  2022cites this paper
• A Brief Review on CAR-T Cell Therapy

  2021cites this paper
• Chimeric Antigen Receptor-T Cells: A Pharmaceutical Scope

  2021cites this paper
• Programmable and multi-targeted CARs: a new breakthrough in cancer CAR-T cell therapy

  2020cites this paper
• Novel usage of CAR T cell therapy in treatment of hematological malignancies and solid tumors: Shift in paradigm of biomarkers

  2020cites this paper
• Chimeric Antigen Receptor T Cells: Development and Production

  2020influential citation
• Chimeric Antigen Receptor T-cell Therapy for Relapsed or Refractory Large B-cell Lymphoma – Latest Data from the ZUMA-1 Study

  2019cites this paper
• In Vitro-Transcribed (IVT)-mRNA CAR Therapy Development.

  2019cites this paper
• The Importance of Collection, Processing & Biopreservation Best Practices in Determining CAR-T Starting Material Quality

  2018cites this paper